5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium

L. N. Thomas, R. C. Douglas, J. P. Vessey, R. Gupta, D. Fontaine, R. W. Norman, I. M. Thompson, D. A. Troyer, R. S. Rittmaster, C. B. Lazier

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Purpose: In the prostate testosterone is converted to the more potent androgen dihydrotestosterone by the enzymes 5α-reductase (5αR) types 1 (5αR1) and 2 (5αR2). Since 5αR2 is the dominant prostatic enzyme, the 5αR2 selective inhibitor finasteride has been widely used to treat benign prostatic hyperplasia (BPH). However, inhibition of both 5αR enzymes provides a greater decrease in serum dihydrotestosterone. We developed a specific antibody to 5αR1 and assessed expression in BPH and prostate cancer (pCa) tissue. The presence of this isoenzyme in localized prostate cancer would provide a rationale for assessing the efficacy of dual inhibition for prostate cancer prevention. Materials and Methods: A polyclonal antibody to 5αR1 was developed and validated using 5αR1 and 5αR2 transfected COS-1 cells. A total of 26 BPH and 53 pCa specimens were assessed for 5αR1 protein expression using immunocytochemical methods. Also, 29 BPH and 37 pCa specimens were assayed for 5αR1 and 5αR2 enzyme activity. Results: Specificity of the 5αR1 antibody was confirmed using transfected COS-1 cells. Cells transfected with 5αR1 showed specific staining in immunocytochemistry experiments and on Western blotting of cell lysates the expected 24 kDa band was observed. High intensity immunoreactivity for 5αR1 was observed in the tumor epithelium of 28% of pCa specimens. No high intensity epithelial staining was observed in BPH specimens. In 19% of pCa and 7% of BPH specimens 5αR1 enzyme activity was detected. Conclusions: The presence of increased 5αR1 in some prostatic malignancies suggests that it is worthwhile to investigate the use of a dual 5αR inhibitor to prevent or treat early stage prostate cancer.

Original languageEnglish (US)
Pages (from-to)2019-2025
Number of pages7
JournalJournal of Urology
Volume170
Issue number5
DOIs
StatePublished - Nov 2003

Fingerprint

Prostatic Hyperplasia
Prostatic Neoplasms
Oxidoreductases
Epithelium
Enzymes
Dihydrotestosterone
COS Cells
Antibodies
Staining and Labeling
Finasteride
Androgens
Isoenzymes
Testosterone
Prostate
Neoplasms
Western Blotting
Immunohistochemistry
Serum

Keywords

  • Androgens
  • Prostate
  • Prostatic hyperplasia
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Thomas, L. N., Douglas, R. C., Vessey, J. P., Gupta, R., Fontaine, D., Norman, R. W., ... Lazier, C. B. (2003). 5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. Journal of Urology, 170(5), 2019-2025. https://doi.org/10.1097/01.ju.0000091804.20183.81

5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. / Thomas, L. N.; Douglas, R. C.; Vessey, J. P.; Gupta, R.; Fontaine, D.; Norman, R. W.; Thompson, I. M.; Troyer, D. A.; Rittmaster, R. S.; Lazier, C. B.

In: Journal of Urology, Vol. 170, No. 5, 11.2003, p. 2019-2025.

Research output: Contribution to journalArticle

Thomas, LN, Douglas, RC, Vessey, JP, Gupta, R, Fontaine, D, Norman, RW, Thompson, IM, Troyer, DA, Rittmaster, RS & Lazier, CB 2003, '5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium', Journal of Urology, vol. 170, no. 5, pp. 2019-2025. https://doi.org/10.1097/01.ju.0000091804.20183.81
Thomas, L. N. ; Douglas, R. C. ; Vessey, J. P. ; Gupta, R. ; Fontaine, D. ; Norman, R. W. ; Thompson, I. M. ; Troyer, D. A. ; Rittmaster, R. S. ; Lazier, C. B. / 5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. In: Journal of Urology. 2003 ; Vol. 170, No. 5. pp. 2019-2025.
@article{dc0125d75e484fb6b26c36b283d52c96,
title = "5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium",
abstract = "Purpose: In the prostate testosterone is converted to the more potent androgen dihydrotestosterone by the enzymes 5α-reductase (5αR) types 1 (5αR1) and 2 (5αR2). Since 5αR2 is the dominant prostatic enzyme, the 5αR2 selective inhibitor finasteride has been widely used to treat benign prostatic hyperplasia (BPH). However, inhibition of both 5αR enzymes provides a greater decrease in serum dihydrotestosterone. We developed a specific antibody to 5αR1 and assessed expression in BPH and prostate cancer (pCa) tissue. The presence of this isoenzyme in localized prostate cancer would provide a rationale for assessing the efficacy of dual inhibition for prostate cancer prevention. Materials and Methods: A polyclonal antibody to 5αR1 was developed and validated using 5αR1 and 5αR2 transfected COS-1 cells. A total of 26 BPH and 53 pCa specimens were assessed for 5αR1 protein expression using immunocytochemical methods. Also, 29 BPH and 37 pCa specimens were assayed for 5αR1 and 5αR2 enzyme activity. Results: Specificity of the 5αR1 antibody was confirmed using transfected COS-1 cells. Cells transfected with 5αR1 showed specific staining in immunocytochemistry experiments and on Western blotting of cell lysates the expected 24 kDa band was observed. High intensity immunoreactivity for 5αR1 was observed in the tumor epithelium of 28{\%} of pCa specimens. No high intensity epithelial staining was observed in BPH specimens. In 19{\%} of pCa and 7{\%} of BPH specimens 5αR1 enzyme activity was detected. Conclusions: The presence of increased 5αR1 in some prostatic malignancies suggests that it is worthwhile to investigate the use of a dual 5αR inhibitor to prevent or treat early stage prostate cancer.",
keywords = "Androgens, Prostate, Prostatic hyperplasia, Prostatic neoplasms",
author = "Thomas, {L. N.} and Douglas, {R. C.} and Vessey, {J. P.} and R. Gupta and D. Fontaine and Norman, {R. W.} and Thompson, {I. M.} and Troyer, {D. A.} and Rittmaster, {R. S.} and Lazier, {C. B.}",
year = "2003",
month = "11",
doi = "10.1097/01.ju.0000091804.20183.81",
language = "English (US)",
volume = "170",
pages = "2019--2025",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - 5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium

AU - Thomas, L. N.

AU - Douglas, R. C.

AU - Vessey, J. P.

AU - Gupta, R.

AU - Fontaine, D.

AU - Norman, R. W.

AU - Thompson, I. M.

AU - Troyer, D. A.

AU - Rittmaster, R. S.

AU - Lazier, C. B.

PY - 2003/11

Y1 - 2003/11

N2 - Purpose: In the prostate testosterone is converted to the more potent androgen dihydrotestosterone by the enzymes 5α-reductase (5αR) types 1 (5αR1) and 2 (5αR2). Since 5αR2 is the dominant prostatic enzyme, the 5αR2 selective inhibitor finasteride has been widely used to treat benign prostatic hyperplasia (BPH). However, inhibition of both 5αR enzymes provides a greater decrease in serum dihydrotestosterone. We developed a specific antibody to 5αR1 and assessed expression in BPH and prostate cancer (pCa) tissue. The presence of this isoenzyme in localized prostate cancer would provide a rationale for assessing the efficacy of dual inhibition for prostate cancer prevention. Materials and Methods: A polyclonal antibody to 5αR1 was developed and validated using 5αR1 and 5αR2 transfected COS-1 cells. A total of 26 BPH and 53 pCa specimens were assessed for 5αR1 protein expression using immunocytochemical methods. Also, 29 BPH and 37 pCa specimens were assayed for 5αR1 and 5αR2 enzyme activity. Results: Specificity of the 5αR1 antibody was confirmed using transfected COS-1 cells. Cells transfected with 5αR1 showed specific staining in immunocytochemistry experiments and on Western blotting of cell lysates the expected 24 kDa band was observed. High intensity immunoreactivity for 5αR1 was observed in the tumor epithelium of 28% of pCa specimens. No high intensity epithelial staining was observed in BPH specimens. In 19% of pCa and 7% of BPH specimens 5αR1 enzyme activity was detected. Conclusions: The presence of increased 5αR1 in some prostatic malignancies suggests that it is worthwhile to investigate the use of a dual 5αR inhibitor to prevent or treat early stage prostate cancer.

AB - Purpose: In the prostate testosterone is converted to the more potent androgen dihydrotestosterone by the enzymes 5α-reductase (5αR) types 1 (5αR1) and 2 (5αR2). Since 5αR2 is the dominant prostatic enzyme, the 5αR2 selective inhibitor finasteride has been widely used to treat benign prostatic hyperplasia (BPH). However, inhibition of both 5αR enzymes provides a greater decrease in serum dihydrotestosterone. We developed a specific antibody to 5αR1 and assessed expression in BPH and prostate cancer (pCa) tissue. The presence of this isoenzyme in localized prostate cancer would provide a rationale for assessing the efficacy of dual inhibition for prostate cancer prevention. Materials and Methods: A polyclonal antibody to 5αR1 was developed and validated using 5αR1 and 5αR2 transfected COS-1 cells. A total of 26 BPH and 53 pCa specimens were assessed for 5αR1 protein expression using immunocytochemical methods. Also, 29 BPH and 37 pCa specimens were assayed for 5αR1 and 5αR2 enzyme activity. Results: Specificity of the 5αR1 antibody was confirmed using transfected COS-1 cells. Cells transfected with 5αR1 showed specific staining in immunocytochemistry experiments and on Western blotting of cell lysates the expected 24 kDa band was observed. High intensity immunoreactivity for 5αR1 was observed in the tumor epithelium of 28% of pCa specimens. No high intensity epithelial staining was observed in BPH specimens. In 19% of pCa and 7% of BPH specimens 5αR1 enzyme activity was detected. Conclusions: The presence of increased 5αR1 in some prostatic malignancies suggests that it is worthwhile to investigate the use of a dual 5αR inhibitor to prevent or treat early stage prostate cancer.

KW - Androgens

KW - Prostate

KW - Prostatic hyperplasia

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0141988845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141988845&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000091804.20183.81

DO - 10.1097/01.ju.0000091804.20183.81

M3 - Article

C2 - 14532845

AN - SCOPUS:0141988845

VL - 170

SP - 2019

EP - 2025

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -